Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Author:
Affiliation:
1. Howard Hughes Medical Institute, Chevy Chase, MD;
2. Oregon Health & Science University Cancer Institute, Portland, OR
Abstract
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Link
http://ashpublications.org/blood/article-pdf/110/7/2242/483995/zh801907002242.pdf
Reference57 articles.
1. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.;Druker;N Engl J Med,2006
2. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.;Goldman;Curr Opin Hematol,2005
3. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.;Hughes;Blood,2006
4. Frequency of major molecular responses to imatinib or interferon a plus cytarabine in newly diagnosed chronic myeloid leukemia.;Hughes;N Engl J Med,2003
5. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.;Ottmann;Blood,2002
Cited by 518 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Effects of bortezomib on ponatinib-resistant Philadelphia chromosome-positive cells;Leukemia & Lymphoma;2024-02
2. Harmonizing the craft of crafting clinically endorsed small-molecule BCR-ABL tyrosine kinase inhibitors for the treatment of hematological malignancies;European Journal of Pharmaceutical Sciences;2024-02
3. JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers;Cancer Letters;2024-02
4. Chemoproteomics Reveals Glaucocalyxin A Induces Mitochondria‐Dependent Apoptosis of Leukemia Cells via Covalently Binding to VDAC1;Advanced Biology;2023-12-17
5. Unraveling Extremely Damaging IRAK4 Variants and Their Potential Implications for IRAK4 Inhibitor Efficacy;Journal of Personalized Medicine;2023-11-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3